Rigor Reviewed

Rigor-Reviewed Manuscript

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.

Name: Αlpha¹ Rigor Record — Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.
Item: Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.
Rating: 100
Author: Αlpha¹

Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 1 high issue for “Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted, prespecified retrospective biomarker analysis of a phase 3 randomized trial, with strong reporting of ethics, resources, and data availability. Minor gaps include lack of randomization method detail, no power analysis for biomarker endpoints, and no explicit reporting guideline, but these do not undermine the overall rigor.

Both reviewers classified the study as interventional, which is adopted. The analysis is a retrospective biomarker sub-study of an interventional trial; the primary trial design is interventional. The statistics verification recomputed only 2 tests (both consistent); other statistics were not machine-verified. The citation check flagged one reference as not found in registry.

7 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior work on BRAF-V600E mutations, the BEACON CRC trial, and previous studies on acquired resistance alterations. It clearly states the objective to identify molecular correlates of clinical outcomes and define resistance mechanisms. The paper acknowledges gaps in prior research, such as the lack of large randomized trials studying molecular subtypes and resistance mechanisms with BRAF inhibitor combinations.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on BRAF-V600E-mutant mCRC, the BEACON CRC trial results, and the need to understand biomarkers of response and resistance.

Evidence

paraphrase[Introduction, paragraph 1]

“BRAF-V600E mutations occur in approximately 10% of tumors in patients with mCRC and are associated with poor prognosis relative to wild-type BRAF tumors.”

direct quote[Introduction, paragraph 3]

“The objective of this analysis was to identify molecular correlates of clinical outcomes and define resistance mechanisms acquired following treatment.”